ArticleOncoTargets and therapy2014

Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer.

Andrés Redondo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.